Dianthus Posts $1.2B Cash, 75% CIDP Response Rate, and Advances gMG Phase 3
DNTH has more than doubled off its 52-week low of $18.08.
Summary
Dianthus Therapeutics reported $1.2 billion in cash, a 75% response rate in its Phase 3 CIDP trial, and the start of a pivotal gMG study, while also disclosing new insider trading plans.
Key Events · Earnings and Guidance · DNTH
-
Cash Runway Extended to 2030
Cash, cash equivalents and investments totaled $1.2 billion as of June 30, 2026, providing sufficient capital to fund operations into 2030, according to management.
-
Phase 3 CIDP Trial Hits 75% Response Rate
The CAPTIVATE trial's Part A interim analysis showed a 75% response rate (30 of 40 patients) with claseprubart, exceeding the 50% target. The drug was well tolerated with no related serious infections or drug-induced lupus.
-
Phase 3 gMG Trial Initiated
The EMERGE trial, a registrational Phase 3 study of claseprubart in generalized myasthenia gravis, began enrolling patients in June 2026, with top-line results expected in the second half of 2028.
-
Phase 2 MMN Trial Fully Enrolled
The MoMeNtum trial in multifocal motor neuropathy completed enrollment with 46 patients, exceeding its target of 36. Top-line results are expected in December 2026.
Analysis · DNTH · Life Sciences
A fortified balance sheet with $1.2 billion in cash and investments, extending the runway into 2030, stands out as a critical survival signal for clinical-stage Dianthus Therapeutics in its Q2 2026 10-Q. Clinical execution was strong: the Phase 3 CAPTIVATE trial for CIDP delivered a 75% response rate, the Phase 3 EMERGE trial in gMG got underway, and enrollment wrapped up in the Phase 2 MoMeNtum trial for MMN. Operating expenses surged as the pipeline advanced, with R&D spending nearly doubling year-over-year. The filing also disclosed new 10b5-1 trading plans by the CEO and other insiders—pre-planned, but adding a layer of insider selling activity to monitor. While the massive cash cushion and positive clinical data reinforce the investment thesis, rising cash burn and insider selling plans temper the enthusiasm.
At the time of this filing, DNTH was trading at $111.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $18.08 to $114.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.